Obermatt
See Similar Stocks →

Aardvark Therapeutics

NSQ:AARD · US0029421007
PharmaceuticalsX-Small

360

29
EV / EBIT100
Price / Owner Earnings56
Cash yield1
Price/Sales10
Price/Book16
Return on Capital16
Cash Return on Capital9
Return on Equity15
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth54
Long-Term EPS Growth1
Reinvestment71
Price momentum8
Debt load81
Refinancing12
Debt Payback1
Liquidity70
Analyst ratings13
Expectations trend13
Market mood13
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Aardvark Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQGS
Founded2017
Employees37
Websiteaardvarktherapeutics.com
ISINUS0029421007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
RespiratoryObesityEndocrinologyInflammationDiabetesTherapeutics

Description

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company has focused its efforts on…

Analysis

Middle-of-the-road

Aardvark Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Aardvark Therapeutics with its peers
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cognition Therapeutics
NAQ:CGTX
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Veru
NAQ:VERU
23
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →